10,859 Shares in MiMedx Group, Inc. (NASDAQ:MDXG) Bought by Entropy Technologies LP

Entropy Technologies LP bought a new position in shares of MiMedx Group, Inc. (NASDAQ:MDXG) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,859 shares of the company’s stock, valued at approximately $64,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Isthmus Partners LLC raised its stake in MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock worth $27,000 after acquiring an additional 91,714 shares during the period. Blue Trust Inc. acquired a new stake in shares of MiMedx Group during the 3rd quarter worth approximately $30,000. Point72 Asset Management L.P. bought a new stake in shares of MiMedx Group in the 2nd quarter worth approximately $40,000. Quest Partners LLC acquired a new position in MiMedx Group during the 2nd quarter valued at approximately $81,000. Finally, Nemes Rush Group LLC grew its stake in MiMedx Group by 93.6% during the 2nd quarter. Nemes Rush Group LLC now owns 16,224 shares of the company’s stock worth $112,000 after buying an additional 7,844 shares during the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MDXG has been the subject of several analyst reports. Craig Hallum reduced their price target on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 1st. StockNews.com lowered shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $11.00 price target on shares of MiMedx Group in a research note on Thursday, August 1st. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $12.00.

MiMedx Group Price Performance

Shares of NASDAQ MDXG opened at $9.28 on Monday. The stock has a market cap of $1.36 billion, a P/E ratio of 16.87 and a beta of 1.94. The firm’s 50-day simple moving average is $6.30 and its 200 day simple moving average is $6.77. MiMedx Group, Inc. has a fifty-two week low of $5.47 and a fifty-two week high of $9.48. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.